MORRISVILLE, N.C. The U.S. Food and Drug Administration has cleared the second generation of the LipiFlow Thermal Pulsation System, according to a press release from TearScience.
The device is designed to help treat evaporative dry eye by liquefying and evacuating obstructions in the meibomian glands, the release said.
The first generation of the device achieved FDA approval in July 2011. The second-generation device allows the physician to treat both eyes at once and includes an upgraded graphical interface, according to the release.
The new device also can store treatment records on electronic medical record servers, reducing the need to manually document treatment, the release said.
The updated LipiFlow will be commercially available in March, according to the release. Physicians now using the first-generation system will be upgraded to the new system.